University of Thessaly (UTH)
Η συμβολή της σωματικής άσκησης στη βελτίωση της ποιότητας ζωής και στη δραστικότητα της ανοσοθεραπείας σε ασθενείς με καρκίνο πνεύμονα
Abstract
dc:descriptionLung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. The introduction of immune checkpoint inhibitors (ICIs) has profoundly transformed the therapeutic landscape of advanced NSCLC, substantially improving survival and shifting the disease towards a chronic condition for an increasing proportion of patients. Nevertheless, despite these advances, patients frequently experience progressive deterioration in functional capacity, skeletal muscle function, exercise tolerance, respiratory symptoms, and health-related quality of life throughout treatment. Current oncologic practice relies predominantly on clinician-rated performance status, which often fails to detect early physiological decline. Furthermore, evidence supporting pulmonary rehabilitation during active immunotherapy remains scarce, as the available literature has largely focused on heterogeneous patient populations, postoperative rehabilitation, or patients receiving chemotherapy.The primary objective of this doctoral thesis was to investigate the efficacy, safety, and clinical feasibility of a supervised pulmonary rehabilitation programme delivered concurrently with first-line ICI-based therapy in patients with stage IV NSCLC. In parallel, the thesis aimed to comprehensively characterize functional deterioration during immunotherapy, evaluate objective multidimensional assessment tools capable of identifying early physiological decline, investigate the association between systemic inflammatory biomarkers and functional outcomes, identify barriers limiting patient participation in rehabilitation programmes, and provide evidence supporting individualized pulmonary rehabilitation strategies during active oncologic treatment.The principal component of the thesis consisted of a prospective, single-centre randomized controlled trial involving patients with stage IV NSCLC initiating first-line ICI-based therapy. Participants were randomly assigned to either a supervised pulmonary rehabilitation programme or usual care. The intervention comprised sixteen supervised outpatient sessions delivered over eight weeks and incorporated high-intensity interval aerobic exercise, resistance training, balance and proprioceptive training, gait retraining, fine motor exercises, breathing exercises, and respiratory physiotherapy techniques. The primary endpoint was change in six-minute walk distance (6MWD). Secondary outcomes included multidimensional physical performance, lower-limb muscle strength, fine motor dexterity, health-related quality of life, respiratory symptom burden, psychological well-being, systemic inflammatory biomarkers, and exploratory oncologic outcomes, including progression-free survival (PFS) and objective response rate (ORR).Supervised pulmonary rehabilitation resulted in clinically meaningful improvements in functional capacity, multidimensional physical performance, quadriceps muscle strength, fine motor dexterity, respiratory symptoms, and health-related quality of life compared with usual care. Significant reductions in anxiety and depressive symptoms were also observed. Importantly, pulmonary rehabilitation was associated with a significant reduction in the neutrophil-to-lymphocyte ratio (NLR), a well-established biomarker of systemic inflammation and adverse prognosis in advanced NSCLC receiving immunotherapy. Although no statistically significant differences were observed in the remaining inflammatory biomarkers, the improvement in NLR suggests that structured exercise may influence biological pathways related to systemic inflammation and host immune response during active cancer treatment, providing a plausible mechanistic link between functional adaptation and immunological regulation.Although exploratory survival analyses did not demonstrate statistically significant differences in progression-free survival, a favourable numerical trend was observed in patients participating in pulmonary rehabilitation, while no adverse oncologic outcomes related to exercise were identified. Equally important, conventional assessment using ECOG Performance Status failed to detect functional deterioration that was readily identified by objective multidimensional functional assessments, including the Short Physical Performance Battery (SPPB), quadriceps strength testing, and the Nine-Hole Peg Test. These findings highlight the limitations of relying exclusively on clinician-rated performance status and support the incorporation of objective functional assessment into routine oncologic practice.Beyond the randomized clinical trial, this doctoral thesis incorporated a series of secondary analyses and complementary independent studies investigating functional assessment tools, inflammatory biomarkers, predictors of functional decline, barriers to exercise participation, educational interventions promoting rehabilitation uptake, and exploratory predictive models aiming to optimize individualized pulmonary rehabilitation programmes. Collectively, these studies provide a comprehensive understanding of functional impairment during immunotherapy and contribute to the development of a more personalized rehabilitation approach for patients with advanced lung cancer.To the best of our knowledge, this thesis represents one of the first randomized controlled investigations worldwide evaluating a comprehensive supervised pulmonary rehabilitation programme exclusively in patients with stage IV NSCLC receiving first-line immune checkpoint inhibitor therapy. Unlike previous studies, which primarily focused on postoperative patients or individuals undergoing chemotherapy, the present work investigated rehabilitation during active immunotherapy, when physiological reserve remains relatively preserved and preventive intervention may be most effective. The findings support a paradigm shift in thoracic oncology, suggesting that pulmonary rehabilitation should no longer be considered solely a post-treatment recovery strategy but rather an integral component of first-line multidisciplinary cancer care aimed at preserving physiological reserve before clinically overt functional decline occurs.Overall, this doctoral thesis provides novel evidence supporting the safety, feasibility, and clinical effectiveness of early pulmonary rehabilitation during immunotherapy, demonstrates potential biological effects through favourable modulation of systemic inflammation, and highlights the importance of objective multidimensional functional assessment beyond conventional performance status. These findings establish a strong scientific foundation for future multicentre randomized trials and may contribute to the incorporation of pulmonary rehabilitation into future international clinical guidelines and routine treatment pathways for patients with advanced NSCLC receiving immune checkpoint inhibitors.The findings of this doctoral thesis further demonstrate that early functional deterioration during immunotherapy is not adequately captured by conventional clinician-rated performance status alone. Objective multidimensional assessment identified clinically relevant impairments in lower-limb performance, muscle strength, fine motor dexterity and symptom burden despite stable ECOG Performance Status, emphasizing the need for routine implementation of comprehensive functional assessment in thoracic oncology. Early identification of physiological decline may facilitate timely rehabilitation interventions before irreversible loss of functional reserve occurs.Importantly, the present work extends beyond evaluating the effectiveness of pulmonary rehabilitation by providing a comprehensive framework for personalized rehabilitation in advanced lung cancer. Through secondary analyses and complementary studies, this thesis identified clinically meaningful assessment tools capable of detecting early functional impairment, explored biological mechanisms potentially linking exercise with systemic inflammation, investigated barriers limiting patient participation in rehabilitation programmes, evaluated educational strategies to improve adherence, and explored predictive models that may facilitate individualized rehabilitation planning. Together, these investigations contribute to a more comprehensive understanding of functional decline during immunotherapy and provide a foundation for precision pulmonary rehabilitation.The reduction observed in the neutrophil-to-lymphocyte ratio represents a particularly important finding, suggesting that structured exercise may exert favourable biological effects beyond improvements in physical performance. Although the exact mechanisms require further investigation, modulation of systemic inflammation may partially explain the beneficial interaction between exercise and host physiological adaptation during immune checkpoint inhibitor therapy. Future adequately powered mechanistic studies are warranted to clarify the relationship between exercise-induced immunomodulation and oncologic outcomes.Collectively, the evidence generated by this thesis supports a shift from the traditional rehabilitation model, in which pulmonary rehabilitation is introduced only after substantial disability has developed, towards a proactive strategy initiated at the beginning of systemic immunotherapy while physiological reserve remains preserved. Such an approach has the potential to maintain functional independence, improve treatment tolerance, reduce symptom burden, and optimize overall patient-centred outcomes throughout the disease trajectory.In conclusion, this doctoral thesis addresses an important gap in the international literature and represents one of the first randomized investigations exclusively evaluating supervised pulmonary rehabilitation during first-line immune checkpoint inhibitor therapy in patients with advanced NSCLC. The findings demonstrate that early pulmonary rehabilitation is safe, feasible, and clinically effective, providing meaningful improvements in functional capacity, multidimensional physical performance, quality of life, and symptom burden, while also suggesting favourable modulation of systemic inflammation. Beyond the primary randomized trial, the integrated programme of secondary analyses and complementary studies advances current knowledge regarding functional assessment, biological markers, rehabilitation barriers, and individualized intervention strategies. Overall, the results support the integration of pulmonary rehabilitation into routine immunotherapy care pathways and provide a robust scientific basis for future multicentre trials, guideline development, and the establishment of pulmonary rehabilitation as a standard component of comprehensive thoracic oncology care.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Lekka, Christina
- Λέκκα, Χριστίνα
Subjects
dc:subject × 20- Μη μικροκυτταρικός καρκίνος πνεύμονα
- Ανοσοθεραπεία
- Ποιότητα ζωής
- Λειτουργική ικανότητα
- Πνευμονική αποκατάσταση
- Σωματική άσκηση
- Επιβίωση χωρίς πρόοδο της νόσου
- Non-small cell lung cancer
- Pulmonary rehabilitation
- Immunotherapy
- Physical exercise
- Functional capacity
- Progression-free survival
- Quality of life ( QOL)
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ογκολογία
- Clinical Medicine
- Medical and Health Sciences
- Oncology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/63134